Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
about
Affinity and avidity in antibody-based tumor targetingCombination Radioimmunotherapy Approaches and Quantification of Immuno-PETAdvances in the formation, use and understanding of multi-cellular spheroidsApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsImplications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesThe development of immunoconjugates for targeted cancer therapyAntibody Drug Conjugates: Preclinical ConsiderationsHLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic RatsA liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or densityThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapyA systems approach for tumor pharmacokineticsEffect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical modelMultizone paper platform for 3D cell culturesMulticolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft modelMolecular Imaging of Pancreatic Cancer with Antibodies.Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells.Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X.Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitorsVisualizing epithelial expression of EGFR in vivo with distal scanning side-viewing confocal endomicroscope.Combinatorial peptide libraries: mining for cell-binding peptides.A modular IgG-scFv bispecific antibody topology.Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugateIdentification of internalizing human single-chain antibodies targeting brain tumor sphere cells.Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance.Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.Quantum dot loaded immunomicelles for tumor imaging.Targeting of drugs and nanoparticles to tumors.Viral nanoparticles as platforms for next-generation therapeutics and imaging devicesIncorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Potato virus X as a novel platform for potential biomedical applications.T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellMultichannel imaging to quantify four classes of pharmacokinetic distribution in tumorsQuantitating antibody uptake in vivo: conditional dependence on antigen expression levels.Chemically modified antibodies as diagnostic imaging agentsConvergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moietiesInfluence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumorsNanotechnology for energy-based cancer therapiesTargeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody FragmentSpatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer
P2860
Q24613552-4AB9BBD9-67E4-4EB3-B064-D6CA7691A163Q26747546-AED41BDB-3632-453D-88CB-D19CA55DA039Q26828808-92C44CD7-F4C8-4185-A061-584D3B19DC23Q26852287-DECA37F9-184B-4957-A222-FA48B6A688DEQ27007486-6E0FA871-2A58-4181-9CFF-DFC384E26B0CQ27021990-5E17746B-7142-494A-8C1E-D032B3DAF5CCQ27022321-A9BAC21D-AD39-4E9B-B64C-C86D19F5CFDAQ27303777-A3C1FC2C-FC64-4E73-9BC2-67F8C0D0754DQ27308658-635D8AD7-9744-410F-B9AD-2251065341D3Q28257521-40F00E75-380E-495E-9507-FB213ABFB1B6Q28477077-4F57F6B0-7C0B-42CE-9C9D-71A77A528BCFQ28544295-E2C340A2-6455-4276-BBB0-C9513D7C2BC5Q28740410-D637CE3F-A1C8-434F-BA17-CBC71E321504Q28750052-1934C2CE-5199-46E4-B2E8-503CD4644F2EQ30393523-8C7B42E4-73DE-4904-A31B-A78FE66C2EEEQ30500177-D4492AE1-8CB1-4B79-B11F-E7BAB2353CEEQ30527772-5B99154A-C329-4256-9E5B-48382AC82BDAQ30575798-B5E482BB-2A4A-41B9-AB43-A425A9662C94Q30829381-791F6706-5E43-4339-B30F-2FC72DFC7B0DQ31144876-7755C35F-4309-4A29-98AC-00CBE6FA930AQ33519465-335FF6A1-8D5F-408D-B8A4-8DF9BFFEA499Q33520512-CFBFD80C-96DD-4116-A6CC-F3742E16C37AQ33574139-D86E29FE-2852-4C7D-8AE7-E76FF2255AB7Q33620053-7B6E7155-5069-4E83-9A12-705BBC9C39BCQ33635071-8B1382C9-7149-4078-B23A-DE7CBBC01539Q33698791-331846FB-9D12-461D-BA2D-59D03DCE672FQ33721349-33669511-5D75-41A2-9173-1B4AEB06FF2FQ33751710-32673342-D951-4736-B638-63696C12019EQ34168677-79459D73-EC3C-442A-AFCE-69E149B94E25Q34204024-9D2EE9CD-A35C-46F7-826C-0201F466F035Q34219033-C3FC897E-C63B-455C-A1FB-030D6EED4AC3Q34227769-35A8DE8B-C140-49F4-AF8D-81CAD8312632Q34241923-4C2DD969-516D-4E30-B272-34AF37B7F9A0Q34400470-FB76AAD6-04D8-4A0C-9406-82DA83F891C1Q34441433-83F21F0D-E93A-41D0-A0C2-28E7F04265D5Q34575951-C1A2F913-F46F-4507-A3FC-A2186DC97543Q34802043-83C96A6E-94AE-4298-B638-6878475CD425Q35264028-AAFE2E78-E1A7-4FAE-B8D2-E31F5C80091DQ35650818-2F1C92F2-0F65-45E7-832A-02B13E13354DQ35882323-836EA714-3422-4C4C-97E0-4EDFDEA9E18B
P2860
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
@en
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
@nl
type
label
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
@en
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
@nl
prefLabel
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
@en
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
@nl
P2860
P1476
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance
@en
P2093
K Dane Wittrup
Michael M Schmidt
P2860
P304
P356
10.1016/J.ADDR.2008.04.012
P407
P577
2008-04-24T00:00:00Z